BMY Stock Recent News
BMY LATEST HEADLINES
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Big pharma stocks ought to perform well in the current high interest rate environment. Eli Lilly and Bristol Myers Squibb have long been top value plays.
I expected Bristol-Myers Squibb Company stock to keep rising in value through 2023 and perhaps reach triple figures. Instead, the share price has fallen 5% this year as inflationary headwinds and drug pricing issues have weighed heavily on the sector.
This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I sort them in descending order by quality score and break ties with additional metrics.
Despite dealing with a pharmaceutical company, Bristol-Myers Squibb's performance during recessions was mixed and the stock also performed horrible in the last two decades. For fiscal 2022, the company also reported mediocre results.
Investors have assigned a higher multiple to LLY stock due to its robust pipeline and better profitability, as discussed below If we look at stock returns, Eli Lilly, with 15% returns in the last twelve months, has fared better than BMS, down 5%, and the broader S&P 500 index, down 11%.
Bristol Myers Squibb is counting on new approvals to fill the hole left by older medicines. Novo Nordisk is second to none in diabetes care, and it is expanding beyond this area.
Bristol Myers and Verizon both pay above-average dividend yields. These payouts are not only safe but could potentially grow as well.
Investors are often on the lookout for strong companies that may be undervalued and present lucrative long-term opportunities.